News

Vertex Pharmaceuticals (NASDAQ: VRTX) transformed the world of cystic fibrosis (CF) treatment when it launched its first product for the disease 12 years ago. Since then, it's built a CF treatment

Investing in equity markets is a reliable, wealth-growing strategy. In the past 33 years, the S&P 500's average annual return is about 10.6%. It's hard to find a return much better than that

Eli Lilly (NYSE: LLY) has become a big name in the anti-obesity market with the recent approval of Zepbound, which is likely to rake in billions in revenue alongside Mounjaro, the company's diabetes

With Vertex Pharmaceuticals (NASDAQ: VRTX) announcing on June 21 that its therapy VX-880 helped nearly all of the patients with diabetes in a clinical trial to reduce or eliminate their need for

Over the past two decades, the road has been rocky for AT&T (NYSE: T) investors, with the stock price only up close to 5% (not including dividends). This year has been a much-appreciated change of

Ultra-high-yield dividend stocks, or companies with annualized payouts above the 5% mark, tend to underperform the broader markets over periods of less than five years. The core reason is that an

When a company obtains positive news from the Food and Drug Administration (FDA), such as the approval of a treatment or a label expansion, it can mark a milestone for the business and lead to

A few years ago, Eli Lilly (NYSE: LLY) was far from the hottest stock in the biopharmaceutical world. But times have changed. Today, Lilly ranks as the biggest healthcare company in the world. It

Most investors know the phrase "buy low, sell high." It's a fine piece of investing wisdom, but it isn't as straightforward as it seems. Even a company whose shares are performing well can be

U.S. wireless carrier AT&T (NYSE: T) is a polarizing stock among investors. Shares are down nearly 30% in price over the past decade, which is a tough pill to swallow. However, include AT&T's famous

Pfizer (NYSE: PFE) can be a polarizing stock to own right now. Its future remains hazy given that it is facing some troubling patent cliffs and revenue from its COVID-19 vaccine is dwindling. But at

It's been a big year for most stocks, with the S&P 500 index up about 24% over the past 12 months. A rising market is wonderful for the stocks already in your portfolio, but finding new investment

Few biotech companies have made more noise than Viking Therapeutics (NASDAQ: VKTX) this year, and that's saying something. The drugmaker had been a relatively small and unknown player in the

Most retirees prefer low turnover in their investment portfolios. The less drama, the better. That way, they can focus on doing what they enjoy instead of worrying about their investments.

Three

Altimmune (NASDAQ: ALT) and Viking Therapeutics (NASDAQ: VKTX) have a lot of features in common, but, at least for the moment, the performance of their stocks is not one of them. Whereas Viking's

If you're an investor who doesn't already have access to billions in capital, you could probably learn a few things from the folks who do. Luckily, keeping tabs on the world's most successful

What a difference a few months make. Vaccine specialist Novavax (NASDAQ: NVAX) started the year poorly, continuing with the issues it has encountered since mid-2021.

Those headwinds included the

If there is one thing income investors like more than regular dividend payouts, it's regular and growing dividend payouts. Not every corporation can offer that, of course. Some will eventually

The stock market has its ups and downs -- and if you stay invested for decades, you will likely experience your fair share of both bull and bear markets. At the same time, by investing in a diverse

Shares of pharmaceutical giant Pfizer (NYSE: PFE) have been steadily sliding lower over the past year as revenue and profits from the pandemic's vaccine boom dry up. Today, the stock has seemingly

Believe it or not, we're nearly halfway through this decade. The healthcare sector could be in store for monumental changes over the next few years.

These changes should present great opportunities

It's no secret why Pfizer (NYSE: PFE) stock has been struggling this year. Investors are worried about how well the company will be able to do in light of waning demand for its COVID-19 vaccine and

There are things that can affect and sink the stock prices of companies in most industries. One of them is a short-seller report. Axsome Therapeutics (NASDAQ: AXSM), a mid-cap biotech, was recently